1508310-34-6

Basic information

• Product Name: 2-[4-(ethylsulfonyl)phenyl]-N-(4-{[(phenylmethyl)(propyl)amino]methyl}phenyl)acetamide
• Synonyms: 2-[4-(ethylsulfonyl)phenyl]-N-(4-{[(phenylmethyl)(propyl)amino]methyl}phenyl)acetamide
• CAS NO: 1508310-34-6
• Molecular Weight: 464.629
• Mol File: 1508310-34-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-[4-(ethylsulfonyl)phenyl]-N-(4-{[(phenylmethyl)(propyl)amino]methyl}phenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-(ethylsulfonyl)phenyl]-N-(4-{[(phenylmethyl)(propyl)amino]methyl}phenyl)acetamide(1508310-34-6)
• EPA Substance Registry System: 2-[4-(ethylsulfonyl)phenyl]-N-(4-{[(phenylmethyl)(propyl)amino]methyl}phenyl)acetamide(1508310-34-6)

Safety Data

• Hazardous Substances Data: 1508310-34-6(Hazardous Substances Data)

Upstream product

• 1508310-55-1 2-[4-(ethylsulfonyl)phenyl]-N-(4-formylphenyl)acetamide 
• 383135-47-5 2-[4-(ethanesulfonyl)phenyl]acetic acid 
• 19073-14-4 4-(1,3-dioxolan-2-yl)aniline 
• 2403-53-4 2-(4-nitrophenyl)-1,3-dioxolane 
• 555-16-8 4-nitrobenzaldehdye 
• 3583-58-2 2-(4-(ethylthio)phenyl)acetic acid 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 1508310-56-2 2-[4-(ethylsulfonyl)phenyl]-N-{4-[(propylamino)methyl]phenyl}acetamide 
• 100-39-0 benzyl bromide 
• 1099073-00-3 [(4-aminophenyl)methyl](phenylmethyl)propylamine 
• 2032-33-9 N-benzyl-N-propylamine 
• 100-52-7 benzaldehyde 

Relevant articles and documents

Discovery of tert-amine-based RORγt agonists

The nuclear receptor retinoic acid receptor-related orphan receptor gamma-t (RORγt) is a transcription factor regulating Th17 cell differentiation and proliferation from naive CD4+ T cells. Since Th17 cells have demonstrated the antitumor efficacy by eliciting remarkable activation of CD8+ T cells, RORγt agonists could be applied as potential small molecule therapeutics for cancer immunotherapy. Based on the previously reported RORγt agonist 1 and its resolved co-crystal structure, a series of new tertiary amines were designed, synthesized and biologically evaluated, yielding optimal moieties with improved chemical properties and biological responses. The combination of these optimal moieties resulted in identification of novel RORγt agonists such as 8b with further elevated RORγt agonism responses at a target-based level as well as in cell-based assays, which provided some structural knowledge for further optimization of RORγt agonists as small molecule therapeutics for cancer immunotherapy.